Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

Unlike Ozempic, Wegovy is approved for weight management even though they both contain semaglutide. However, they do have ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

CNN’s 5 Things newsletter is your one-stop shop for the latest headlines and fascinating stories to start and end your busy day. Sign up here.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...